|Bid||79.53 x 1100|
|Ask||79.56 x 1100|
|Day's range||79.11 - 80.27|
|52-week range||55.80 - 85.07|
|PE ratio (TTM)||9.94|
|Earnings date||23 Jul 2018 - 27 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||86.00|
Express Scripts Holding Company (NASDAQ:ESRX), a large-cap worth US$45.26b, comes to mind for investors seeking a strong and reliable stock investment. Big corporations are much sought after by risk-averse investorsRead More...
After briefly terminating its deal with start-up PillPack two years ago, Express Scripts is now in a similar spat with CareZone.
Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.
York Capital Management founder Jamie Dinan expects a wave of mergers now that a federal judge has ruled the AT&T-Time Warner deal can move forward.
FILE: The CVS Health Corp. signage is displayed outside a pharmacy store in downtown Los Angeles, California, U.S., on Friday, Oct. 27, 2017. It’s been a good week for CVS Health and Aetna with a judge clearing the AT&T-Time Warner merger and now the nation’s largest doctor group staying quiet on the drugstore chain’s proposed acquisition of the nation’s third-largest health insurance company. Wall Street is cheering a federal judge’s ruling that the U.S. Justice Department failed to prove that AT&T’s $85 billion purchase of Time Warner violated antitrust deals.
Amazon and AT&T pursued the deal in part due to new competition from video streaming services like Netflix and Amazon.
Court approval of the AT&T-Time Warner deal now makes it more likely that similar kinds of pending mergers will go through — and there’s a good investing angle in this. The green light in the deal appears to clear the way for CVS Health’s (CVS) planned acquisition of insurer Aetna (AET), and Cigna’s (CI) pending takeover of pharmacy-benefit manager (PBM) Express Scripts (ESRX).
A federal judge's ruling late Tuesday blessing the AT&T-Time Warner merger raised hopes that the CVS-Aetna and Cigna-Express Scripts deals will win antitrust approval.
Health care and telecom stock futures responded after a federal judge approved AT&T's merger of Time Warner. Markets await a Fed rate policy decision on Wednesday.
Let’s talk about the popular Express Scripts Holding Company (NASDAQ:ESRX). The company’s shares saw a decent share price growth in the teens level on the NasdaqGS over the last fewRead More...
Express Scripts (ESRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CVS Health Corp. is buying Aetna Inc., while Cigna Corp. is snapping up Express Scripts Holding Co. As health-care companies vertically integrate with high-priced deals across varied parts of the industry’s supply chain, Walgreens Boots Alliance Inc.(WBA) , its acquisition of rival Rite Aid’s (RAD)nearly 2,000 stores now complete, remains alone at the party. See: U.S. health care is changing in a big way.
Last week, the Trump administration, via secretary of health and human services, Alex Azar, proposed that drug makers be required to include the list prices of drugs in all direct-to-consumer ads. In addition, payers are providing support for the prices being set. Just last week, Amgen announced that the price of its new migraine drug, Aimovig, would be set at $6,900 per year.
Biotech companies and pharmacy benefit managers defied the overall market trend, despite more noise about President Trump's drug plan.
ValueAct now holds 16.2 million Citigroup shares. In other major first-quarter moves, ValueAct exited its positions in Microsoft (MSFT) and pharmacy benefit manager Express Scripts (ESRX). Perhaps the writing was on the wall about Microsoft.
Healthcare investors who were on the edges of their seats on Friday afternoon were relieved. Share prices of potentially-affected “middlemen” such as pharmacy-benefit managers, and to a lesser extent health insurers, fell sharply but then rebounded within minutes in late trading. After all, Mr. Trump’s comments were characteristically vague and didn’t unveil any immediate action to cut drug spending that might harm the profitability of companies like Express Scripts Holding or CVS Health.
WASHINGTON—President Donald Trump unveiled dozens of initiatives aimed at curbing high drug prices Friday, a raft of modest moves that left the pharmaceutical industry relieved and buoyed their stocks. “We’re going to take on one of the biggest obstacles to affordable medicine: the tangled web of special interests,” Mr. Trump said from the White House Rose Garden.
Trump's plan to lower drug prices in the U.S. is "fair to all players" in the health-care industry, GOP Sen. Bill Cassidy argues.
President Donald Trump this afternoon unveiled his plan to crack down on high-priced drugs. Pharmaceutical industry investors were unfazed. In fact, the stocks of the firms he hit hardest—the "middlemen" known as pharmacy-benefit managers—jumped as traders saw little in the administration's program that could hurt PBM outfits like Express Scripts Holding (ESRX) and CVS Health (CVS), the parent of the benefit business Caremark.
U.S. President Donald Trump on Friday blasted drugmakers and healthcare "middlemen" for making prescription medicines unaffordable for Americans, but healthcare stocks rose as his administration avoided aggressive direct measures to cut prices. Trump made the remarks at the White House Rose Garden in a speech to introduce what he called "the most sweeping action in history" to lower drug prices. Trump said his administration would take aim at the "middlemen" in the drug industry who became "very, very rich," an apparent reference to health insurers and pharmacy benefit managers (PBMs).
Alex Azar, secretary of Health and Human Services, speaks as Donald Trump listens during an event on lowering drug prices outside the White House in Washington, D.C., U.S., on Friday, May 11, 2018. “We're very much eliminating the middlemen,” Trump said of his administration’s proposed “American Patients First” blueprint to lower prices.
Health care stocks whipsawed on Friday as President Donald Trump unveiled his long-awaited plan to lower prescription drug prices, dubbed "American Patients First."